Evidence map›Paper›PMID 34093191›Full record

ArticleFrontiers in pharmacology2021

Pharmacogenetic Associations Between Atazanavir/

Daniela Poblete, Fernando Bernal, Gabriel Llull, Sebastian Archiles, Patricia Vasquez, Leonardo Chanqueo, Nicole Soto, María A Lavanderos, Luis A Quiñones, Nelson M Varela

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daniela PobleteLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Fernando BernalDepartment of Infectious Diseases, Hospital San Juan de Dios, Santiago, Chile.
Gabriel LlullClinical Laboratory, Hospital San Juan de Dios, Santiago, Chile.
Sebastian ArchilesClinical Laboratory, Hospital San Juan de Dios, Santiago, Chile.
Patricia VasquezDepartment of Infectious Diseases, Hospital San Juan de Dios, Santiago, Chile.
Leonardo ChanqueoDepartment of Infectious Diseases, Hospital San Juan de Dios, Santiago, Chile.
Nicole SotoLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
María A LavanderosLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Luis A QuiñonesLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Nelson M VarelaLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Hospital San Juan de Dios · CLUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADRsantiretroviralatazanavirCYP2B6efavirenzHIVpharmacogeneticUGT1A1

Identifiers

PMID34093191
PMCPMC8170096
OpenAlexW3160312313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.